戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lly, a subset of asthmatics are resistant to steroid therapy.
2  is self-limited and resolves with prolonged steroid therapy.
3 mune pancreatitis and to monitor response to steroid therapy.
4 is defined by primary resistance to standard steroid therapy.
5 th the start of the first course of standard steroid therapy.
6 des in this group, and none of them required steroid therapy.
7 ed management in the intensive care unit and steroid therapy.
8 A and that they change in patients receiving steroid therapy.
9 om one patient whose rash did not respond to steroid therapy.
10  and resolution again with re-institution of steroid therapy.
11 ively) after adjusting for race, income, and steroid therapy.
12   A majority of patients with DBA respond to steroid therapy.
13 d both rapidly responded to reinstitution of steroid therapy.
14 llow-up of >4 months are no longer receiving steroid therapy.
15 gic diseases can be difficult to diagnose by steroid therapy.
16 rom disease and enhance the effectiveness of steroid therapy.
17   Of the 430 patients with SAH, 132 received steroid therapy.
18 hs' follow-up has led to continuation of the steroid therapy.
19  are candidates for rapid tapers of systemic steroid therapy.
20 d showed no overall change over 12 months of steroid therapy.
21   Patients with CoNV unresponsive to topical steroid therapy.
22 y occlusion) or receiving post-I/R high-dose steroid therapy.
23 d within the first month after initiation of steroid therapy.
24 tients (23%) had previous failure to topical steroid therapy.
25 herapy for hepatitis C, and who responded to steroid therapy.
26 ection, or hypopyon, and responds to topical steroid therapy.
27 dosterone system antagonists with or without steroid therapy.
28 t was subsequently successfully treated with steroid therapy.
29 n diagnosis was higher in patients receiving steroid therapy.
30 nd none of the patients with cancer received steroid therapy.
31  antibiotic therapy, and 1 received systemic steroid therapy.
32  to 30 and 31 to 90 days after initiation of steroid therapy.
33  adjustment for the propensity for receiving steroid therapy.
34 ival, and if this effect is synergistic with steroid therapy.
35 ancreatic organ involvement, and response to steroid therapy.
36 ymptoms have been managed with intratympanic steroid therapy.
37 stases were asymptomatic and did not require steroid therapy.
38 -related disease or to disease relapse after steroid therapy.
39 mmunosuppression and can include maintenance steroid therapy.
40 , and consideration for drotrecogin alfa and steroid therapy.
41  with minimal change disease and response to steroid therapy.
42 es and Hazleman criteria and had not started steroid therapy.
43 eet our definition of a complete response to steroid therapy.
44    All recipients remain free of maintenance steroid therapy.
45 ilder than those of commonly used, prolonged steroid therapies.
46 ation of these cells either due to asthma or steroid therapies.
47 d longer telomere length was associated with steroid therapy (0.29 +/- 0.14; P = 0.046).
48 ly developed nephrotic syndrome resistant to steroid therapy 1 week after orthopedic surgery.
49  issues: (1) the diagnosis and proper use of steroid therapy, (2) the concerns about the choice betwe
50                                 With topical steroid therapy 5 times per day during the first postope
51  HR PK, when the VEGFR1_MO was combined with steroid therapy, a significant increase in graft surviva
52 en the Flt23k nanoparticle was combined with steroid therapy, a significant increase in graft surviva
53 nsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser
54  influence the response to antimicrobial and steroid therapies and the risk of lung infection.
55 t trends toward improved freedom from pulsed-steroid therapy and biopsy-confirmed rejection over grou
56 Pediatric SAFS was associated with more oral steroid therapy and higher IL-33 levels.
57 ease asthma exacerbations requiring systemic steroid therapy and hospitalization.
58  treated effectively with aggressive topical steroid therapy and lubrication.
59                        Two patients required steroid therapy and one required rabbit antithymocyte gl
60                         Methods: The STOPPE (Steroid Therapy and Outcome of Parapneumonic Pleural Eff
61 th cessation of vaping, supportive care, and steroid therapy and remained symptom free at follow up.
62 e reactivation allowed early introduction of steroid therapy and resolution of the clinical picture.
63 function did not differ between those on QOD steroid therapy and those on QD therapy.
64 y to clarify which patients may benefit from steroid therapy and to examine long-term effects of ster
65 pulations of patients are often resistant to steroid therapy, and determining the molecular mechanism
66 on among electroencephalogram abnormalities, steroid therapy, and neuropsychological findings.
67 nitiation, rate, and complications following steroid therapy, and taper regimens in the setting of se
68 s fail to satisfactorily respond to standard steroid therapy, and this type of steroid-resistant, sev
69              Beneficial for clinical trials, steroid therapy, and transplant indications, it's access
70 induced immune arthritis and its response to steroid therapy before joint destruction.
71 apy (i.e., tonsillectomy combined with pulse steroid therapy) but not in patients on comprehensive su
72      Early intensified postoperative topical steroid therapy constitutes an effective prophylactic tr
73 hose patients who did not respond to initial steroid therapy demonstrated a worse long-term survival
74 ation in the pancreatic LN, although topical steroid therapy did not enhance this.
75         Seven of 63 patients (11%) receiving steroid therapy died compared with 10 of 23 (43%) not re
76 ternative use of immunosuppressive agents to steroid therapy, disease remission in refractory neuro-o
77  undergone hepatoportoenterostomy, high-dose steroid therapy following surgery did not result in stat
78 nts received even empiric bolus or high-dose steroid therapy for a presumed rejection episode.
79           Among allo-HSCT patients receiving steroid therapy for acGVHD, lymphocyte binding to dermal
80  the potentially detrimental consequences of steroid therapy for anthrax must be considered in treatm
81 HIV (n=1), concomitant CGD and DM (n=1), and steroid therapy for nephrotic syndrome (n=1).
82                  Patients undergoing chronic steroid therapy for organ transplantation are at increas
83         The patient was discharged and given steroid therapy for presumed IgG4-related disease.
84 old man who developed the infection while on steroid therapy for rheumatoid arthritis.
85 d with better vision outcomes than long-term steroid therapy for sympathetic ophthalmia treatment.
86 roles of surgical decompression and systemic steroid therapy for TON, these interventions have not be
87 organisms were previous surgery, malignancy, steroid therapy, foreign body, and immunodeficiency.
88 tropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood p
89                                    Antenatal steroid therapy had a borderline-significant protective
90                        Individuals receiving steroid therapy had significantly higher levels of Asper
91 chieving only moderate success with systemic steroid therapy, he was ultimately treated with recombin
92 is of CCS was made and after initiation of a steroid therapy his diarrhea improved immediately.
93 ancreatic organ involvement, and response to steroid therapy improve the diagnostic yield for AIP.
94                                              Steroid therapy improved language outcomes independently
95  for corticosteroid function in vivo and for steroid therapies in various clinical settings.
96 teroids in 123 patients (93.2%), intravenous steroid therapy in 35 patients (26.5%), cyclosporine in
97 ease-modifying antirheumatic drug (DMARD) or steroid therapy in 8 of the patients originally treated
98 ophageal ulceration ultimately responsive to steroid therapy in a 31-year old immunosuppressed, human
99 rhea associated with combined antibiotic and steroid therapy in critically ill patients not fitting i
100                                      Chronic steroid therapy in kidney transplantation has myriad sid
101  mechanism but also help us to better manage steroid therapy in liver diseases.
102 ents, can be normalized by high-dose inhaled steroid therapy in severe asthma.
103 ulties in obtaining clinical remission under steroid therapy in some patients, resulting in long dura
104                                      Chronic steroid therapy in spite of myriad side effects is widel
105  a novel mechanism explaining the benefit of steroid therapy in these patients.
106                          Clinical outcome of steroid therapy in this patient cohort correlated with i
107 d common bile duct strictures resolved after steroid therapy in three patients.
108 ients; use of genetic techniques and topical steroid therapy in treating graft-versus-host disease; a
109 on of zafirlukast therapy in three patients, steroid therapy in two patients, and orthotopic liver tr
110 ne dysregulation and immune suppression from steroid therapy increase the risk.
111 ficantly increased within 5 to 30 days after steroid therapy initiation and attenuated during the sub
112 ve surgical procedures such as intratympanic steroid therapy, intratympanic gentamicin therapy, and e
113                        In patients with DMD, steroid therapy is associated with a substantial reducti
114                                              Steroid therapy is associated with an increased risk of
115                                              Steroid therapy is the current mainstay of treatment of
116 of severe decompensation with no response to steroid therapy, it represents an effective treatment.
117 9%, respectively, for patients not receiving steroid therapy (log-rank p = 0.0005).
118                                              Steroid therapy may be useful for acute or recalcitrant
119 lantation is not impaired, and postoperative steroid therapy may prevent EM.
120 , if patients do not adequately benefit from steroid therapy, mortality is high and standardized trea
121                          With hourly topical steroid therapy none of the patients developed CME subse
122                                              Steroid therapy normalized liver enzyme levels in 61%; b
123 This study sought to determine the impact of steroid therapy on cardiomyopathy and mortality in patie
124                                The effect of steroid therapy on IL-33 levels in patients with neonata
125 ty of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and at
126 gastrointestinal tract, the patient received steroid therapy, only for 2 months.
127 ose with clear indications such as long-term steroid therapy or vertebral fractures on radiography, d
128 r cataract surgery and topical postoperative steroid therapy (P = .0143).
129 d compared with 10 of 23 (43%) not receiving steroid therapy (p = 0.0010).
130 lts in uncertainties associated with inhaled steroid therapy prescription.
131  understanding of the immune landscape after steroid therapy, providing a potential markers of therap
132  either long-term dietary control or chronic steroid therapies, rather than the acid-suppressive medi
133 solution of neurologic symptoms with initial steroid therapy, relapse after withdrawal of steroids, a
134    Permanent coronary occlusion or high-dose steroid therapy significantly reduced myocardial water c
135  intraocular pressure with topical NSAID and steroid therapy that resolved when the topical NSAID was
136 vere asthmatic children exposed to high dose steroid therapy, therefore bronchoscopy with BAL should
137                             Short-term pulse steroid therapy to treat acute rejection was necessary f
138 eturned to normal after treatment with pulse steroid therapy to treat the rejection episode.
139  intravenous immunoglobulin, with adjunctive steroid therapy used in one-third.
140 ons responded to combined antitubercular and steroid therapy, usually spared fovea, and had a good fi
141  78.6%, respectively, for patients receiving steroid therapy versus 100%, 72.1%, and 27.9%, respectiv
142 steroid resistant UC patients on concomitant steroid therapies was used.
143 e of biopsy-proven acute rejection requiring steroid therapy was 6.7% in both groups.
144                                      Chronic steroid therapy was able to deplete the T cell products
145                                        Pulse steroid therapy was associated with rapid improvement of
146 ee years, all polyps had disappeared and the steroid therapy was finished while the dosage of mesalaz
147                       Incomplete response to steroid therapy was more frequent in C4d-diffuse/focal c
148                                              Steroid therapy was most effective in the resolution of
149                     A discontinuation of the steroid therapy was not possible and mesalazine (1000 mg
150 eated attained remission and the response to steroid therapy was similar among the groups (classic sc
151 er discontinuation of all drugs, he received steroid therapy was started and clinical findings improv
152                                              Steroid therapy was withdrawn during the observation per
153 is in groups treated with both VEGFR1_MO and steroid therapy were also analyzed in HR PK.
154  a group treated with both nanoparticles and steroid therapy were also analyzed.
155 r decreased antibodies after bortezomib plus steroid therapy were identified.
156   Response rates of Banff grades I and II to steroid therapy were not different, but only 42% of grad
157                                        Early steroid therapy withdrawal in standard-risk patients aft

 
Page Top